Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings

Arcutis Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.72 EPS, expectations were $-0.65. Arcutis Biotherapeutics, Inc.

Related Keywords

Mizuho , Hokkaido , Japan , United States , Sean Kim , Vikram Purohit , Tyler Van Buren , Seamus Fernandez , Frank Watanabe , John Smither , Chris Shibutani , Serge Belanger , Patrick Burnett , Arcutis Biotherapeutic , Todd Edwards , Derek Cole , Arcutis Biotherapeutics Inc , Goldman Sachs , Trademark Office , Nasdaq , Morgan Stanley , Exchange Commission , Call Transcript February , Full Year Financial Results Conference , Arcutis Investor , Chief Medical Officer , Chief Commercial Officer , Chief Financial , Janus Kinase , Medical Congresses , Lasting Jeans Brands , Ecommerce Companies , Van Buren , Atopic Dermatitis , Partd Medicare ,